Friday 6 November 2026
Export RMD’s income statement to Excel — free account
ResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.
- Revenue
- +5.93%
- EPS
- +23.1%
- Free cash flow
- −9.79%
- Total debt
- −38.9%
Quarter to September 2026, against a year earlier
238.80
1.71
−0.71%
Follow RMD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
20.08 | 18.63 | 21.58 | 23.73 |
+8 more quarters Free account |
P/S ratio |
5.51 | 5.02 | 5.89 | 6.51 | |
P/FCF ratio |
19.90 | 17.41 | 18.79 | 19.77 | |
P/Operating CF |
74.84 | 62.38 | 58.88 | 103.40 | |
P/B ratio |
5.32 | 4.31 | 5.03 | 5.56 | |
Price to Tangible BV |
12.17 | 8.80 | 10.79 | 12.34 | |
EV/Sales |
5.38 | 4.83 | 5.66 | 6.32 | |
EV/EBITDA |
14.48 | 12.81 | 14.55 | 16.52 | |
EV/Operating CF |
17.42 | 15.11 | 16.60 | 17.82 | |
EV/FCF |
19.42 | 16.76 | 18.07 | 19.20 | |
Quick Ratio |
1.50 | 1.80 | 1.97 | 1.93 | |
Current Ratio |
2.65 | 3.10 | 3.01 | 3.06 | |
Net Debt/EBITDA |
(1.51) | (2.12) | (2.21) | (1.83) | |
Debt/Assets |
3.04% | 4.45% | 4.60% | 4.75% | |
Debt/Equity |
0.04 | 0.06 | 0.06 | 0.06 | |
Asset Turnover |
0.69 | 0.66 | 0.68 | 0.69 | |
Operating CF/Net income |
1.01 | 1.19 | 1.39 | 0.87 | |
Capex/Depreciation |
(0.99) | (1.04) | (0.57) | (0.55) | |
Interest Coverage |
94.10 | (12.19) | (40.68) | (61.85) | |
Research and Development Expense of Revenue |
7.27% | 7.08% | 6.59% | 6.39% | |
Selling, General and Administrative Expense of Revenue |
22.24% | 18.71% | 19.96% | 19.57% | |
Intangible Assets out of Total Assets |
0.41 | 0.38 | 0.39 | 0.41 | |
Share Based Compensation of Revenue |
2.08% | 1.88% | 1.87% | 2.03% | |
Graham Net Nets |
0.04 | 0.07 | 0.05 | 0.05 | |
Graham Number |
101.51 | 103.20 | 102.24 | 99.49 | |
Earnings Yield |
4.98% | 5.37% | 4.63% | 4.21% | |
Free Cash Flow Yield |
5.02% | 5.74% | 5.32% | 5.06% | |
Revenue per Share |
9.89 | 10.06 | 9.85 | 9.76 | |
Operating CF per Share |
2.95 | 3.12 | 3.81 | 2.33 | |
Capex per Share |
(0.36) | (0.39) | (0.27) | (0.24) | |
Free Cash Flow per Share |
2.60 | 2.73 | 3.54 | 2.09 | |
Cash per Share |
7.07 | 10.10 | 11.43 | 9.72 | |
Shareholders Equity per Share |
41.60 | 45.25 | 44.67 | 43.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
41.60 | 45.25 | 44.67 | 43.34 | |
Free Cash Flow |
371.25 | 397.38 | 514.54 | 305.19 | |
Working Capital |
2,184.70 | 2,929.63 | 2,712.85 | 2,570.69 | |
Capital Expenditures |
(51.17) | (57.25) | (39.59) | (34.55) | |
Net Current Asset Value |
1,244.80 | 1,944.18 | 1,771.69 | 1,636.31 | |
EV/EBIT |
16.30 | 14.46 | 16.58 | 18.76 | |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.02 | |
Price to Operating Income |
16.70 | 15.03 | 17.24 | 19.31 | |
| Other line items | |||||
Average Receivables |
939.88 | 987.86 | 953.33 | 922.79 | |
Average Payables |
293.73 | 293.54 | 247.93 | 235.36 | |
Average Inventory |
983.58 | 936.76 | 887.26 | 902.07 | |
Average Assets |
8,260.08 | 8,570.17 | 8,175.55 | 7,822.35 | |
Average Common Equity |
6,034.48 | 6,276.63 | 6,019.02 | 5,786.94 |
Columns are period end dates · fundamentals updated 5 Nov 2026